AstraZeneca PLC AstraZeneca prices a EUR1.5bn bond offering (0503R)
February 24 2023 - 1:15PM
UK Regulatory
TIDMAZN
RNS Number : 0503R
AstraZeneca PLC
24 February 2023
24 February 2023 18:15 GMT
AstraZeneca prices EUR1.5 billion bond offering
AstraZeneca PLC ("AstraZeneca") announces that, on 24 February
2023, it successfully priced EUR750 million of fixed rate notes
with a coupon of 3.625% maturing on 3 March 2027 and EUR750 million
of fixed rate notes with a coupon of 3.750% maturing on 3 March
2032 (the "Notes").
AstraZeneca expects to use the net proceeds of the offering for
general corporate purposes, including refinancing of existing
indebtedness.
The Notes will be issued under the US$10,000,000,000 EMTN
programme of AstraZeneca and AstraZeneca Finance LLC and admitted
to listing on the UK Financial Conduct Authority's Official List
and to trading on the London Stock Exchange's Main Market.
The Notes have not been registered under the U.S. Securities Act
of 1933 and may not be offered or sold in the United States absent
registration or an applicable exemption from registration.
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the Notes described herein, nor
shall there be any sale of these Notes in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IODPPUUPPUPWGMC
(END) Dow Jones Newswires
February 24, 2023 13:15 ET (18:15 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024